PGDIS工作组关于PGT-A现状的报告
PGDIS工作组评估了PGT-A在IVF中的临床价值与有效性,综合技术、遗传学原理和临床结局研究后认为,正确实施PGT-A能提高胚胎选择的获益,并期望该报告能消除围绕PGT-A的困惑、促进知情选择并最终改善移植结局。
要点
- 正确实施PGT-A可提高IVF胚胎选择的获益
- 部分学会对PGT-A的声明含糊,使胚胎选择的潜力不确定
- PGDIS工作组综合技术、遗传学与临床结局证据评估PGT-A
核心结论
- 正确实施PGT-A可增加IVF胚胎选择的获益。
研究设计与样本
- PGDIS工作组汇总科学信息并批判性评估PGT-A临床价值的证据。
主要发现
- 部分主要学会2024年关于PGT-A的声明含糊,使胚胎选择的潜力与获益不确定。
- 工作组从技术方面、遗传学原理和临床结局研究进行考量。
临床怎么用
- 应正确实施PGT-A以优化IVF胚胎选择并改善移植结局。
- 临床决策应基于对PGT-A证据的知情选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The clinical utility and validity of preimplantation genetic testing for aneuploidies (PGT-A) in IVF practice is often questioned. Some major societies (Practice Committees of the American Society for Reproductive Medicine and the Society for Assisted Reproductive Technology 2024) have released ambiguous statements about PGT-A, leaving the potential and benefits of embryo selection, enhanced by chromosome profile assessments, indeterminant. The Preimplantation Genetic Diagnosis International Society (PGDIS) Task Group has gathered the scientific information and critically evaluated the evidence about the clinical value of PGT-A. We considered technical aspects, genetic principles and clinical outcome studies, and conclude that the proper implementation of PGT-A results in increased benefits for IVF embryo selection. It is envisioned that this report will remove some of the confusion surrounding PGT-A, lead to informed choices about the use of PGT-A and ultimately result in improved transfer outcomes.
引用
- Leigh D, Scott RT, Rechitsky S, et al. Report of the PGDIS Task Group on the status of PGT-A. Reprod Biomed Online. 2026. PMID: 41980563. doi:10.1016/j.rbmo.2026.105498
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。